Literature DB >> 902665

Congenital adrenal hyperplasia: renin and steroid values during treatment.

D B Grant, M J Dillon, S M Atherden, R J Levinsky.   

Abstract

Plasma renin activity (PRA), aldosterone (Aldo), 17alpha-hydroxyprogesterone (17-OHP) and testosterone (T), together with urine sodium, pregnanetriol, 17-oxosteroids and the 11-oxygenation index (11-OH) were estimated in 23 patients (age 5.7--18 yrs.) with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency during glucocorticoid treatment. Elevated PRA levels (1400--17200 ng Al/l/hr) were found in 13 out of 15 patients with a history of salt loss. Three non-salt losers showed high PRA levels and in the remaining 5 the levels were in the upper normal range (540--900 ng Al/l/hr). Plasma Aldo levels were normal (25--620 pmol/l) in 18 patients and slightly elevated (690--2360 pmol/l) in 5. While these results indicate persistent impairment of sodium homeostasis in CAH patients, no significant correlations between log. PRA, log. Aldo and urinary sodium excretion were found. Mid-day 17-OHP levels ranged from 9 to 117 nmol/l and T from 0.3 to 18.0 nmol/l. Neither the 17-OHP nor the T results correlated well with the clinical assessment of therapeutic control. The results of the urinary steroid determinations showed better agreement with the clinical assessment of treatment and the 17-oxosteroid, pregnanetriol and 11-OH index results appeared to be better discriminants between good and poor control. Twelve of the patients with a history of early salt loss were reinvestigated after one month's treatment with oral 9 alpha-flurohydrocortisone (0.05 mg/day). PRA was reduced in 7 patients and 17-OHP fell in 10 patients. No consistent changes were found in Aldo, T, or urinary sodium and steroid excretion during this low-dose mineralocorticoid treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902665     DOI: 10.1007/bf00443127

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  Inhibition of the sodium-retaining influence of aldosterone by progesterone.

Authors:  R L LANDAU; K LUGIBIHL
Journal:  J Clin Endocrinol Metab       Date:  1958-11       Impact factor: 5.958

2.  Diagnosis of congenital adrenal hyperplasia by measurement of plasma 17-hydroxyprogesterone.

Authors:  N D Barnes; S M Atherden
Journal:  Arch Dis Child       Date:  1972-02       Impact factor: 3.791

3.  Serum 17-alpha-hydroxyprogesterone, progesterone, estradiol, and testosterone in the diagnosis and management of congenital adrenal hyperplasia.

Authors:  B M Lippe; S H LaFranchi; N Lavin; A Parlow; J Coyotupa; S A Kaplan
Journal:  J Pediatr       Date:  1974-12       Impact factor: 4.406

4.  Congenital adrenal hyperplasia and other conditions associated with a raised urinary steroid 11-oxygenation index.

Authors:  B E Clayton; R W Edwards; H L Makin
Journal:  J Endocrinol       Date:  1971-06       Impact factor: 4.286

5.  Secretion rates of cortisol and aldosterone precursors in various forms of congenital adrenal hyperplasia.

Authors:  M I New; M P Seaman
Journal:  J Clin Endocrinol Metab       Date:  1970-03       Impact factor: 5.958

6.  Letter: Congenital adrenal hyperplasia.

Authors:  G M Komrower; C C Bailey
Journal:  Arch Dis Child       Date:  1974-10       Impact factor: 3.791

7.  Circadian variation in plasma 17-hydroxyprogesterone in patients with congenital adrenal hyperplasia.

Authors:  S M Atherden; N D Barnes; D B Grant
Journal:  Arch Dis Child       Date:  1972-08       Impact factor: 3.791

8.  Plasma renin activity in congenital virilizing adrenal hyperplasia.

Authors:  M Imai; Y Igarashi; H Sokabe
Journal:  Pediatrics       Date:  1968-05       Impact factor: 7.124

9.  Plasma renin activity and aldosterone secretion in congenital adrenal hyperplasia.

Authors:  C Godard; A M Riondel; R Veyrat; A Mégevand; A F Muller
Journal:  Pediatrics       Date:  1968-05       Impact factor: 7.124

10.  Exchangeable sodium and aldosterone secretion in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  B Loras; F Haour; J Bertrand
Journal:  Pediatr Res       Date:  1970-03       Impact factor: 3.756

View more
  7 in total

1.  Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency.

Authors:  P E Mullis; P C Hindmarsh; C G Brook
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

2.  The interaction of plasma renin activity and plasma atrial natriuretic peptide in 21-hydroxylase deficiency patients.

Authors:  C M R Germano; M de Castro; J C Crescencio; L Gallo; J Antunes-Rodrigues; A C Moreira; L L K Elias
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

3.  [Problems and characteristics of the orthodontic treatment of a patient with adrenogenital syndrome].

Authors:  J W Schlupper-Beckmann; M Lücke; R Mallmann
Journal:  Fortschr Kieferorthop       Date:  1989-10

4.  Plasma renin activity in the management of congenital adrenal hyperplasia.

Authors:  K D Griffiths; J M Anderson; B T Rudd; N K Virdi; G Holder; P H Rayner
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

5.  Mineralocorticoid deficiency and treatment in congenital adrenal hyperplasia.

Authors:  Raja Padidela; Peter C Hindmarsh
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-04

6.  17-hydroxyprogesterone, androstenedione, and testosterone in normal children and in prepubertal patients with congenital adrenal hyperplasia.

Authors:  K von Schnakenburg; F Bidlingmaier; D Knorr
Journal:  Eur J Pediatr       Date:  1980-05       Impact factor: 3.183

7.  Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia.

Authors:  I A Hughes; A Wilton; C A Lole; O P Gray
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.